Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORADIL vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Long-term maintenance treatment of asthma,Prevention of exercise-induced bronchospasm,Maintenance treatment of chronic obstructive pulmonary disease (COPD)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Metabolized primarily by hepatic glucuronidation and to a lesser extent by CYP2D6, CYP2C19, and CYP2C9.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
61% bound to plasma proteins, primarily albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
6.0 L/kg (extensive tissue distribution, indicating high penetration into lungs and peripheral tissues).
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Inhalation: ~30% (systemic absorption from lungs; oral bioavailability negligible due to first-pass metabolism).
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No dose adjustment required for renal impairment.
No data; not applicable.
No specific dose adjustment recommended; use caution in severe hepatic impairment.
No data; not applicable.
Children 5 years and older: 12 mcg inhalation twice daily. No dosing established for children under 5 years.
No data; not applicable.
No specific dose adjustment; monitor for adverse effects due to potential comorbidities.
No data; not applicable.
LABAs increase the risk of asthma-related death; Foradil should only be used in patients with asthma not adequately controlled on asthma controller medications or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
None
Increased risk of asthma-related death,Deterioration of disease and acute episodes may occur and should be treated with a short-acting beta2-agonist,Cardiovascular effects (increased heart rate, blood pressure, ECG changes),Hypokalemia and hyperglycemia may occur,Paradoxical bronchospasm may occur and require immediate discontinuation,Do not use with other LABAs
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to formoterol or any ingredient in the formulation,Use as monotherapy in asthma without concomitant inhaled corticosteroid,Treatment of acute asthma symptoms or exacerbations
Hypersensitivity to arformoterol or any component of the formulation
No specific food interactions. Grapefruit/grapefruit juice may increase systemic exposure via CYP3A4 inhibition; avoid concurrent use.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
FDA Pregnancy Category C. In animal studies, formoterol fumarate (active ingredient of FORADIL) showed adverse effects on fetal development at high doses, including increased fetal loss, decreased fetal weight, and skeletal variations. There are no adequate and well-controlled studies in pregnant women. During first trimester, risk cannot be ruled out. Second and third trimesters: potential risk of maternal beta-agonist effects causing uterine relaxation and delayed labor. Use only if potential benefit justifies potential risk to fetus.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Formoterol is excreted in human milk in small amounts. M/P ratio not established. Caution should be exercised when administered to nursing women. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for FORADIL and any potential adverse effects on the breastfed infant from the drug or underlying maternal condition.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
No specific dose adjustments are recommended for FORADIL during pregnancy based on pharmacokinetic changes. However, use the lowest effective dose to control asthma symptoms. Monitor for potential increased need for rescue medication due to pregnancy-related changes in asthma severity. No data indicate significant pharmacokinetic changes requiring dosing modification.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
FORADIL (formoterol fumarate) is a long-acting beta2-agonist (LABA) indicated for maintenance treatment of asthma and COPD, but must not be used as monotherapy for asthma without concomitant inhaled corticosteroid. Onset of bronchodilation occurs within 5-10 minutes, peaking at 1-3 hours, with duration up to 12 hours. Not for acute bronchospasm. Risk of paradoxical bronchospasm; discontinue if occurs. Monitor for increased heart rate, blood pressure, and QTc prolongation. Caution in patients with cardiovascular disorders, seizure disorders, thyrotoxicosis, or diabetes.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Use FORADIL exactly as prescribed; do not use to relieve sudden breathing problems.,Always have a fast-acting rescue inhaler (e.g., albuterol) for acute symptoms.,Do not use more than 2 inhalations every 12 hours; maximum daily dose is 48 mcg.,Rinse mouth with water after each use to reduce risk of thrush (if using with ICS).,Seek medical help immediately if breathing worsens, chest tightness, or hives develop.,Inform your doctor if you have heart disease, high blood pressure, seizures, thyroid problems, or diabetes.,Store capsules in blister pack, use only with provided Aerolizer inhaler; do not swallow capsules.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORADIL vs AEROLONE, answered by our medical review team.
FORADIL is a Bronchodilator that works by Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORADIL and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORADIL is: Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORADIL and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORADIL is classified as Category C. FDA Pregnancy Category C. In animal studies, formoterol fumarate (active ingredient of FORADIL) showed adverse effects on fetal development at high doses, including increased fetal. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.